1′-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3′-indol]-2′(1’H)-one | |
---|---|
Trade Name | |
Orphan Indication | Erythromelalgia |
USA Market Approval | USA |
USA Designation Date | 2012-11-19 00:00:00 |
Sponsor | Teva Pharmaceuticals;41 Moores Road, P. O. Box 4011;Frazer, Pennsylvania, 19355 |
Related Access Program